TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05299827

Intervention type: OTHER
Intervention: The same evaluation methods were used for both groups.
Description: No treatment applied to participants and same evaluation methods used in both groups. Trunk muscle strength, muscle endurance, posture, flexibility and pelvic floor muscle activity of participants was evaluated with stabilizer pressurized biofeedback unit, sit-ups and modified push-ups test; trunk flexors endurance test and Modified Biering Sorensen Test; Posture Screen Mobile And Foot Posture Index; sit-reach-test and Beighton Score; and NeuroTrac-Myoplus4Pro,

Intervention type: OTHER
Intervention: The same evaluation methods were used for both groups.
Description: No treatment applied to participants and same evaluation methods used in both groups. Trunk muscle strength, muscle endurance, posture, flexibility and pelvic floor muscle activity of participants was evaluated with stabilizer pressurized biofeedback unit, sit-ups and modified push-ups test; trunk flexors endurance test and Modified Biering Sorensen Test; Posture Screen Mobile And Foot Posture Index; sit-reach-test and Beighton Score; and NeuroTrac-Myoplus4Pro,
Study: NCT04743414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543
Description: Itraconazole in solution dosage form
Study: NCT06440590

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: suprapectineal quadrilateral buttress plating
Description: 15 cases will undergo anatomical supra-pectineal quadrilateral plate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infra-pectineal plating
Description: 15 cases will undergo conventional manually contoured infra-pectineal plate
Study: NCT04445116

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Action Video Game Treatment
Description: Endeavor™ is a digital, non-drug investigational treatment that is delivered through an action video game and is designed to target cognitive deficits in adolescence and young adults with pediatric onset MS.
Study: NCT06037538

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood glucose measurement by subject
Description: blood glucose measurement by subject using finger tip capillary blood
Study: NCT06012838

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cause classification of OHCA protocol
Description: training program with cause classification of OHCA protocol
Study: NCT06037538

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood glucose measurement with reference
Description: blood glucose measurement with reference method using finger tip capillary blood
Study: NCT05122754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: Bictegravir/emtricitabine/tenofovir alafenamide once daily, 1 tablet at a time, with or without food for 48 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF-based triple ART regimen switching to B/F/TAF
Description: Tenofovir disoproxil fumarate was administered once daily, one tablet at a time, with or without food. After Week 24, control subjects were also switched to bictegravir/emtricitabine/tenofovir alafenamide once daily, one tablet at a time, with or without food for the later 24 weeks.
Study: NCT05616949

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU) (Arm 1)
Description: Treatment as Usual (TAU): The treatment and/or other services received as part of usual care while living in a recovery residence. This arm serves as the active comparator group for the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Recovery Support Services (PRSS) + TAU (experimental- Arm 2)
Description: Peer Recovery Support Services (PRSS) Intervention: The experimental group for this study that involves the implementation of the PRSS intervention. This study will test the preliminary efficacy of the PRSS intervention on Medications for Opioid Use Disorder (MOUD) retention by evenly randomizing N=50 individuals on MOUD living in recovery residences (RRs) to either a 24-week course of the experimental PRSS intervention layered on top of treatment as usual services
Study: NCT05585411

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Left bundle branch area pacing
Description: LBBAP success is defined if ventricular lead is successfully placed at interventricular septum and RBB configuration observed during unipolar tip pacing.~LBB capture is defined if fulfilling criterion 1 and at least one in criteria 2.~1. RBBB configuration observed during unipolar tip pacing~2. One of the following should be met:~   1. Abrupt shortening of Stim-LVAT (stimulus to peak of the R wave in V6 \[LV activation time\]) of \>10ms during increasing output~  2. Short and constant stim-LVAT and the shortest stim-LVAT \<75ms in non-LBBB and \<85ms in LBBB~  3. Programmed stimulation by pacing lead changes QRS morphology from nonselective LBB to LV septal capture~  4. LBB potential (LBB-V interval of 15 to 35ms)~  5. Transition from nonselective LBB capture to selective LBB capture at near threshold outputs~If criterion 1 is fulfilled but none in criteria 2 is met, the procedure is considered to be deep septal pacing (DSP).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Right ventricular pacing
Description: Right ventricular pacing is the traditional pacing modality for ventricular pacing. Implantation of a RV pacing lead (apex or septum of right ventricle) will be attempted using the standard-of-care technique first
Study: NCT05078567

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 5% Natural Lactic Acid-enriched Cream
Description: The subjects were required to topically apply natural lactic acid-enriched cream twice daily in the morning and evening for the treatment duration of 12 weeks.
Study: NCT05164952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid 4 MG
Description: (4 mg via 15-min infusion every 6 months) for 24 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid 4 MG
Description: (4 mg via 15-min infusion every 6 months) for 24 months
Study: NCT05091801

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Participants will have one week of increased chewing time (chew food until they reach an apple sauce consistency)
Study: NCT05815121

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressing
Description: Acupuncture with placement of 4 vaccaria seeds covered with stickers on the ears and 2 on the wrists.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: with stickers only on the points, and the points should not be massaged.
Study: NCT04863287

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2217LS
Description: Fully Human Monoclonal Antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2217LS
Description: Fully Human Monoclonal Antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2217LS
Description: Fully Human Monoclonal Antibody
Study: NCT05719467

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buscopan 20 MG/ML Injectable Solution
Description: 1 mL intravenously
Study: NCT04863287

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2217LS
Description: Fully Human Monoclonal Antibody

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride (NaCl)
Description: Subcutaneous injection
Study: NCT06570707

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brighter Bites
Description: Families will receive a distribution of fresh fruits and vegetables (FV) (\~20lbs., 50 servings/family/distribution) for \~16 weeks during the school year using primarily donated produce from local food banks. Nutrition education will be implemented for children using the evidence-based Coordinated Approach to Child Health (CATCH) program and for parents using bilingual nutrition handbooks and fun food experiences such as healthy FV recipe tastings for families during produce pick-up time will be conducted.
Study: NCT05638386

Intervention type: PROCEDURE
Intervention: Bone plug
Description: The investigational treatment is the use of a bone plug in the two drill-holes in the tibia, made by two pins for securing the tibial array to the bone. The pins that are used for this, are 4.0mm wide. The bone plug that is used to fill the drill-holes of tibia, is obtained from the bone that is removed during the operation to make place for the new prosthesis. A piece as wide as the drill-hole is cut off the recessed bone and put into this hole. After this, the wound is closed using surgical staples.
Study: NCT05221294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified Del Nido Versus Custodiol Cardioplegia
Description: Modified Del Nido Versus Custodiol Cardioplegia For Myocardial Protection In Cardiac Surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified Del Nido Versus Custodiol Cardioplegia
Description: Modified Del Nido Versus Custodiol Cardioplegia For Myocardial Protection In Cardiac Surgery
Study: NCT05173272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Therapy
Description: Cisplatin 50 mg/m\^2 d1 q21+ Paclitaxel 175 mg/m\^2 d1 q21+serplulimab 300mg d1 q21

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CCRT
Description: weekly cisplatin for 4 or 5 weeks is administered concomitant with EBRT (45-50.4Gy) in 1.8-2 daily fractions and a 10-20 Gy boost to reach a total dose of 65 Gy when there was unresectable lymph nodes.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CCRT
Description: weekly cisplatin for 4 or 5 weeks is administered concomitant with EBRT (45-50.4Gy) in 1.8-2 daily fractions and a 10-20 Gy boost to reach a total dose of 65 Gy when there was unresectable lymph nodes.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: The primary cervical tumor is the boosted, using image guided 3D brachytherapy or 2D brachytherapy, with an additional 30-40 Gy to HRCTV (3D brachytherapy) or to point A (2D brachytherapy), to achieve a total dose of 80 Gy for small-volume cervical tumors or 85 Gy for larger-volume cervical tumors.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: The primary cervical tumor is the boosted, using image guided 3D brachytherapy or 2D brachytherapy, with an additional 30-40 Gy to HRCTV (3D brachytherapy) or to point A (2D brachytherapy), to achieve a total dose of 80 Gy for small-volume cervical tumors or 85 Gy for larger-volume cervical tumors.
Study: NCT05186558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: penpulimab, lenalidomide, Rituximab, Gemcitabine, Oxaliplatin
Description: Patients receive penpulimab+R2-GemOx two weeks for a cycle, detailed as follows:~Combination therapy Anti-PD-1 antibody (penpulimab): Fixed dose of 200 mg every 2 weeks, d0, intravenous drip (without pretreatment), for 6 cycles.~R2-GemOx: lenalidomide 10 mg，d1-7; Rituximab 375mg/m2, d0; Gemcitabine 1000mg, d1; Oxaliplatin 100mg/m2, d1; every 2 weeks for a cycle, 6 cycles as protocol specified.~Maintenance treatment:~Combination of two drugs:~* Anti-PD-1 antibody (penpulimab): Fixed dose of 200 mg every 2 weeks, d0, intravenous drip (without pretreatment), , for 6 months~* lenalidomide: 10 mg, po, for 18 months.
Study: NCT04982965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Cannabis
Description: 400 mg of vaporized and inhaled active cannabis (5.1%)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cannabis
Description: 400 mg of vaporized and inhaled placebo cannabis (\<.1%)
Study: NCT06386653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diagnostic injection of [123I]I-DARPIN-Ec1
Description: A single intravenous injection of \[123I\]I-DARPIN-Ec1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diagnostic injection of [123I]I-DARPIN-Ec1
Description: A single intravenous injection of \[123I\]I-DARPIN-Ec1

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Whole-body planar scintigraphy with [123I]I-DARPIN-Ec1
Description: Gamma camera-based whole-body planar scintigraphy imaging 2, 4, 6, and 24 hours after a single intravenous injection of \[123I\]I-DARPIN-Ec1

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Whole-body planar scintigraphy with [123I]I-DARPIN-Ec1
Description: Gamma camera-based whole-body planar scintigraphy imaging 2, 4, 6, and 24 hours after a single intravenous injection of \[123I\]I-DARPIN-Ec1

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Whole-body SPECT with [123I]I-DARPIN-Ec1
Description: Whole-body SPECT at 2, 4, and 6 hours after a single intravenous injection of \[123I\]I-DARPIN-Ec1

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Whole-body SPECT with [123I]I-DARPIN-Ec1
Description: Whole-body SPECT at 2, 4, and 6 hours after a single intravenous injection of \[123I\]I-DARPIN-Ec1
Study: NCT03789773

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Millimeter-Wave Holographic Imaging
Description: Undergo mm-wave holographic imaging
Study: NCT04908189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Deucravacitinib
Description: Specified dose on specified days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days

Intervention type: DRUG
Group type: OTHER
Intervention: Apremilast
Description: Specified dose on specified days
Study: NCT05905328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTO1681 10 μg
Description: Administered 3 times daily for 15 days (initial cohort).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTO1681 20 μg
Description: Administered 3 times daily for 15 days (successive cohort).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTO1681 30 μg
Description: Administered 3 times daily for 15 days (successive cohort).
Study: NCT06200467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 456906
Description: Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BI 456906
Description: Solution for injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to BI 456906
Description: Solution for injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to BI 456906
Description: Solution for injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin
Description: Film-coated tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to moxifloxacin
Description: Film-coated tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to moxifloxacin
Description: Film-coated tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to moxifloxacin
Description: Film-coated tablet
Study: NCT06287047

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural analgesia
Description: Epidural analgesia alone or with dural puncture with different sizes of spinal needles

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural analgesia
Description: Epidural analgesia alone or with dural puncture with different sizes of spinal needles

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural analgesia
Description: Epidural analgesia alone or with dural puncture with different sizes of spinal needles
Study: NCT05453370

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CALMA m-health app
Description: CALMA is an app for smartphones that provides evidence-based tools to prevent suicide. Out of Crisis modality consists of 4 sections: Moments, Agenda, Profile and Tips. The I need help modality uses DBT skills presented in a card format. The Problem-solving Card is the first one showed and helps the user to know if the problem that triggered the crisis can be addressed through a problem-solving strategy. If not, the next step is to use the CALMA thermometer (to identify the intensity of the emotion) and the DBT Skills Cards. They are based fundamentally in two groups of DBT skills, emotional regulation and distress tolerance. If distress worsens or does not diminish the Emergency Card is activated, offering the user the option to make one or several calls to emergency contacts and providing the option to use the geolocation function to show all emergency services near the user's location so that he/she can consult personally. All participants will also receive mental health treatment.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment As Usual (TAU)
Description: Participants who do not receive the application will continue the usual mental health treatment (psychotherapeutic and/or psychopharmacological) by their usual treating professionals throughout the duration of the study.
Study: NCT06438276

Intervention type: BEHAVIORAL
Intervention: Psychiatric outreach nurse service
Description: Mental health service provided by psychiatric outreach nurses for 12-16 year old students in secondary schools
Study: NCT05914272

Intervention type: DRUG
Intervention: Osmotic drugs
Description: Patients had used osmotic drugs within 72 hours of admission.

Intervention type: DRUG
Intervention: Osmotic drugs
Description: Patients had used osmotic drugs within 72 hours of admission.
Study: NCT06457321

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sequence in receiving the fabricated dentures made using the conventional and partial digital method
Description: Participants is not informed on the sequence they have been randomized hence they are not able to determine which denture is fabricated from which method. This would reduce bias when collecting the participants' responses in the satisfaction questionnaire during the review visits.
Study: NCT05892185

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GELA
Description: GELA glaucoma implant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: XEN
Description: XEN gel stent implant
Study: NCT05719467

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buscopan 20 MG/ML Injectable Solution
Description: 1 mL intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium bicarbonate
Description: 4 g orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium bicarbonate
Description: 4 g orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 4g orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4g orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nacl 0.9%
Description: 1 mL intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nacl 0.9%
Description: 1 mL intravenously
Study: NCT05783869

Intervention type: DEVICE
Intervention: Echocardiography
Description: echocardiographic study of both groups
Study: NCT04848688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin 2 mg
Description: Monotherapy, oral administration, single-dose, fixed-dose, 4 tablets of 2 mg each to yield an 8 mg final dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin 3 mg
Description: Monotherapy, oral administration, single-dose, weight dependent, The number of tablets will be adjusted according to the patients' weight to yield 200 ug/kg final dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Monotherapy, oral administration, single dose, matching number of tablets to either moxidectin or ivermectin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Monotherapy, oral administration, single dose, matching number of tablets to either moxidectin or ivermectin
Study: NCT05995769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Single dosing session followed by 5 MET weekly sessions starting 24hrs after dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psilocybin
Description: Single dosing session followed by 5 MET weekly sessions starting 24hrs after dosing
Study: NCT05554887

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thrust manipulation
Description: Participants will be positioned prone and the clinician will perform a high-speed, low-amplitude thrust into the most symptomatic segment of the thoracic spine. TM type, thrust direction, and number of thrusts will be at the clinician's discretion and will be based on the individualized assessment of the patient.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham thrust manipulation
Description: The same protocol will be applied as the push thoracic manipulation application, but no push will be applied.
Study: NCT06306157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose naltrexone
Description: While naltrexone is FDA-approved for treatment of alcohol or opioid addition, this study will be looking at how naltrexone, when dosed very low, may reduce the painful symptoms associated with CRPS. Naltrexone is not FDA-approved for pain management treatment of CRPS at this time, and therefore the study intervention is using the drug in an off-label manner.
Study: NCT05930925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [phenyl-14C]ARV-471
Description: Participants will receive a single dose of \[phenyl-14C\]ARV-471 by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [oxoisoindolin-14C]ARV-471
Description: Participants will receive a single dose of \[oxoisoindolin-14C\]ARV-471 by mouth
Study: NCT06306157

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sugar capsules
Description: The external appearance of the capsules prepared by the pharmacy will be identical to the LDN capsules. The inactive capsule ingredients will be microcrystalline cellulose (MCC) and Magnesium stearate
Study: NCT04798417

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic supplement
Description: Use of a probiotic sachet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic supplement
Description: Prebiotic sachets

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Placebo comparator
Study: NCT05415059

Intervention type: DEVICE
Group type: OTHER
Intervention: Covatech Stoma bag material
Description: Strips of Covatech Stoma bag used to asses adhesion of 3M material to be used in LEAFix device
Study: NCT05788328

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran etexilate (DE)
Description: Dabigatran etexilate (DE) as oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate (DE)
Description: Dabigatran etexilate (DE) as oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate (DE)
Description: Dabigatran etexilate (DE) as oral capsule
Study: NCT05200442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VS-6766/avutometinib
Description: An oral anti-cancer medication.
Study: NCT05788328

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Rosuvastatin as oral tablet